Related Experiment Videos
Methotrexate for multiple sclerosis
The Cochrane Database of Systematic Reviews
|April 24, 2004
Summary
Methotrexate may offer a slight benefit in reducing relapses and disease progression for multiple sclerosis (MS). However, current evidence is limited, necessitating further clinical trials to confirm efficacy and safety in MS patients.
Area of Science:
- Neurology
- Immunology
Background:
- Methotrexate is an immunosuppressant with theoretical benefits for multiple sclerosis (MS).
- Clinical trials have investigated methotrexate's efficacy in managing MS progression and relapses.
Purpose of the Study:
- To evaluate the efficacy and safety of methotrexate for individuals with multiple sclerosis.
- To identify and summarize existing evidence on methotrexate's impact on MS relapse rates and disease progression.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) of methotrexate for MS.
- Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to June 2001.
- Included one trial of 60 participants with chronic progressive MS; contacted authors for missing data.
Main Results:
- The included trial showed a non-significant trend towards reduced EDSS progression and relapses with methotrexate.
- No significant difference in time to first relapse was observed.
- Minor side effects were common in both methotrexate and placebo groups, with no major adverse events reported.
Conclusions:
- A single trial suggests a non-significant trend favoring methotrexate for progressive MS.
- Further rigorous trials are required to establish the efficacy of methotrexate in multiple sclerosis.
- Existing evidence is insufficient to draw definitive conclusions on methotrexate's role in MS management.